Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANNOVIS BIO, INC.

(ANVS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Annovis Bio, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

07/28/2021 | 03:52pm EDT

Annovis Bio, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 2.534 million compared to USD 2.543 million a year ago. Net loss was USD 2.524 million compared to USD 2.309 million a year ago. Basic loss per share from continuing operations was USD 0.34 compared to USD 0.34 a year ago. For the half year, operating loss was USD 5.763 million compared to USD 3.126 million a year ago. Net loss was USD 5.724 million compared to USD 2.751 million a year ago. Basic loss per share from continuing operations was USD 0.8 compared to USD 0.48 a year ago.


ę S&P Capital IQ 2021
All news about ANNOVIS BIO, INC.
09/21INVESTOR ALERT : Kirby McInerney LLP Reminds Investors That a Securities Class Action Laws..
BU
09/19SHAREHOLER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their Investment..
PR
09/15KESSLER TOPAZ MELTZER & CHECK, LLP : Securities Fraud Class Action Filed Against Annovis B..
PR
09/15SHAREHOLDER ALERT : Robbins LLP Announces that Annovis Bio, Inc. (ANVS) is Being Sued for ..
BU
09/13ANNOVIS BIO : Pomerantz Law Firm Announces the Filing of a Class Action Against Annovis Bi..
PR
09/13GLANCY PRONGAY & MURRAY LLP : Reminds Investors of Looming Deadline in the Class Action La..
PR
09/09DEADLINE REMINDER : Law Offices of Howard G. Smith Reminds Investors of Looming Deadline i..
PR
09/08ANVS CLASS ACTION DEADLINE : Bernstein Liebhard LLP Reminds Investors of the Deadline to F..
PR
09/07ANNOVIS BIO : The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class ..
PR
09/05SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Annov..
PR
More news
Analyst Recommendations on ANNOVIS BIO, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -12,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -20,7x
Yield 2021 -
Capitalization 269 M 269 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 2
Free-Float 69,6%
Chart ANNOVIS BIO, INC.
Duration : Period :
Annovis Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANNOVIS BIO, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 33,16 $
Average target price 150,00 $
Spread / Average Target 352%
EPS Revisions
Managers and Directors
Maria-Luisa Maccecchini President, Chief Executive Officer & Director
Jeffrey B. McGroarty Chief Financial Officer
Michael B. Hoffman Chairman
Cheng Fang Vice President-Research
Claudine E. Bruck Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ANNOVIS BIO, INC.339.79%269
GILEAD SCIENCES, INC.23.12%89 936
BIONTECH SE318.73%82 443
WUXI APPTEC CO., LTD.36.63%69 407
REGENERON PHARMACEUTICALS33.91%67 262
VERTEX PHARMACEUTICALS-21.38%48 202